

ESC Declaration of Interests Report

2024 ESC Guidelines for the management of elevated blood pressure and hypertension

The ESC reviews relationships with healthcare industry and encourages transparency and ethical integrity.

It is mandatory for all experts involved in the development of ESC Guidelines to comply with the ESC Declaration and Management of Conflict of Interest Policy. Under this policy, they are required to submit a yearly Declaration of Interests (DOI) during the writing and reviewing phases of the Guidelines.

All DOIs presented in this report were assessed prior to work commencing and during the development of the Guidelines, according to the applicable review criteria in place at the time and as defined in the ESC Declaration and Management of Conflict of Interest Policy, Annex 3.

The most up-to-date version of the policy and its annexes are available on the ESC website at www.escardio.org/DOI.

2024 ESC Guidelines for the management of elevated blood pressure and hypertension - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Brouwers Sofie	2021 Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Servier : Arterial hypertension Menarini : Arterial hypertension Merck Sharp & Dohme : Arterial hypertension Daiichi Sankyo : Lipids Sanofi Aventis : Lipids
	2022 Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Medtronic : Risk Factors and Prevention Novartis : Risk Factors and Prevention Servier : Risk Factors and Prevention Sanofi Aventis : Risk Factors and Prevention Menarini : Risk Factors and Prevention Sandoz : Risk Factors and Prevention
	2023 Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Janssen-Cilag : Echocardiography Amgen : Risk Factors and Prevention Daiichi Sankyo : Risk Factors and Prevention Novartis : Risk Factors and Prevention Servier : Risk Factors and Prevention
Bruno Rosa Maria	2021 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Medtronic : Renal Denervation
	2022 Nothing to be declared

2024 ESC Guidelines for the management of elevated blood pressure and hypertension - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry	
Bruno Rosa Maria	2023	Nothing to be declared
Canavan Michelle	2021	Nothing to be declared
	2022	Nothing to be declared
	2023	Nothing to be declared
Ceconi Claudio	2021	Nothing to be declared
	2022	Nothing to be declared
	2023	Nothing to be declared
Christodorescu Ruxandra Maria	2021	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Pfizer : Antithrombotic Therapy Viatrix : Dyslipidemia Servier : Heart Failure Boehringer-Ingelheim : Heart Failure Pharmacotherapy</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. Servier : Interventional Cardiology</p>
	2022	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Pfizer : Atrial Fibrillation (AF) Astra Zeneca : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Zentiva : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Servier : Hypertension Viatrix : Risk Factors and Prevention</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. Novartis : Chronic Heart Failure</p>

2024 ESC Guidelines for the management of elevated blood pressure and hypertension - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Christodorescu Ruxandra Maria	<p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Pfizer : Atrial Fibrillation (AF) Novartis : Chronic Heart Failure Boeringer Ingelheim : Chronic Heart Failure Astra Zeneca : Chronic Heart Failure, Acute Coronary Syndromes Servier : Hypertension Berlin Chemie AG : Hypertension</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Pfizer : Atrial Fibrillation (AF) Astra Zeneca : Chronic Heart Failure</p>
Daskalopoulou Stella S	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Servier : 2 Webinars on Hypertension control in Hypertension Canada Annual Conference for CME</p> <hr/> <p>2022</p> <p>Nothing to be declared</p> <hr/> <p>2023</p> <p>Research funding from healthcare industry received personally by you or an entity controlled by you. Servier</p>
Ferro Charles	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bayer : Diabetic Nephropathy</p> <hr/> <p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bayer : Pharmacology and Pharmacotherapy</p> <hr/> <p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Bayer AG : Cardiovascular Disease in Special Populations CSL vifor : Cardiovascular Disease in Special Populations</p>

2024 ESC Guidelines for the management of elevated blood pressure and hypertension - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry	
Ferro Charles	2023	<p>Membership or affiliation in political or advocacy groups working in the field of cardiology. Represent the European Kidney Health Alliance on the European Alliance for Cardiovascular Health</p>
Gerdtz Eva	2021	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bayer AG : Speaker fee, Podcast Women in Cardiology</p>
	2022	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bayer AG : Hypertension Novo Nordisk : Risk Factors and Prevention</p>
	2023	<p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astellas : Other</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). I am member of the editorial boards of the journals Blood Pressure and High Blood Pressure and Cardiovascular Prevention.</p>
Hanssen Henner	2021	Nothing to be declared
	2022	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Medtronic : Hypertension</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. Assoc Board - EAPC Council Board - Council on Hypertension EAPC Membership Committee EAPC Secondary Prevention and Rehabilitation Section EAPC Task Force on Childhood Cardiovascular Health</p>
	2023	<p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Medtronic : Hypertension</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. Assoc Board - EAPC Council Board - Council on Hypertension EAPC Membership Committee EAPC Secondary Prevention and Rehabilitation Section EAPC Task Force on Childhood Cardiovascular Health</p>
Harris Julie	2021	Nothing to be declared

2024 ESC Guidelines for the management of elevated blood pressure and hypertension - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry	
Harris Julie	2022	Nothing to be declared
	2023	Nothing to be declared
Lauder Lucas	2021	Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Medtronic : Speaker fee (a total of 366€) for a webinar on resistant hypertension
	2022	Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Recor Medical : Hypertension
	2023	Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca : Chronic Heart Failure Pfizer : Echocardiography Recor Medical : Hypertension
McCarthy Cian	2021	Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astellas : Dr. McCarthy reports receiveing a medical textbook from Astellas Pharma US Inc.
	2022	Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Abbott Laboratories : Acute Coronary Syndromes
	2023	Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Abbott Laboratories : Acute Coronary Syndromes Roche Diagnostics : Acute Coronary Syndromes
Mcevoy John William	2021	Nothing to be declared
	2022	Nothing to be declared
	2023	Nothing to be declared

2024 ESC Guidelines for the management of elevated blood pressure and hypertension - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
McManus Richard	<p>2021</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. OMRON Healthcare : BP monitors for research; fees for consultancy and licensing</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology. Chair BP monitoring working party British and Irish Hypertension Society</p>
	<p>2022</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. OMRON Healthcare : e-Cardiology/Digital Health</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. Chair BP monitoring standing committee British and Irish Hypertension Society</p>
	<p>2023</p> <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity NIHR</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. OMRON Healthcare : Hypertension</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. Chair BIHS BP monitoring standing committee (non financial)</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). I am on the editorial board of hypertension and hypertension research (non financial)</p>
Molloy Gerard	<p>2021</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology. The National Institute for Prevention and Cardiovascular Health https://nipc.ie/about/</p>
	<p>2022</p> <p>Nothing to be declared</p>
	<p>2023</p> <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Health Research Board Irish Research Council</p>

2024 ESC Guidelines for the management of elevated blood pressure and hypertension - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Rahimi Kazem	<p>2021</p> <p>Receipt of royalties for intellectual property. Sensyne Health : Digital heart failure care</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Novo-Nordisk : Heart failure subphenotyping with use of machine learning techniques</p>
	<p>2022</p> <p>Receipt of royalties for intellectual property. Sensyne Health : e-Cardiology/Digital Health</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Novo-Nordisk : Research Grant, University Of Oxford, Co-Principal Investigator</p>
	<p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca : Hypertension</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Medtronic Renal Denervation : Hypertension</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Novo-Nordisk : Research Grant, University Of Oxford, Co-Principal Investigator</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Editor-in-Chief, BMJ Heart</p>
Regitz-Zagrosek Vera	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Abbott : sex and gender Pfizer : sex and gender in CVD</p> <p>Receipt of royalties for intellectual property. Springer : Royalties for 2 medical books edited in 2012</p>

2024 ESC Guidelines for the management of elevated blood pressure and hypertension - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry	
Regitz-Zagrosek Vera	2022	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Other Novartis : Other Pfizer : Other Lilly : Other Chiesi Pharma : Other AbbiVie : Other Synlab : Other</p> <p>Receipt of royalties for intellectual property. Springer : Other</p>
	2023	<p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca : Other Novartis : Other Pfizer : Other Lilly : Other Chiesi Pharma : Other AbbiVie : Other</p> <p>Receipt of royalties for intellectual property. Springer : Other</p>
Rossi Gian Paolo	2021	Nothing to be declared
	2022	Nothing to be declared
	2023	Nothing to be declared

2024 ESC Guidelines for the management of elevated blood pressure and hypertension - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Sandset Else Charlotte	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Boston Scientific : Speaker honoraria Daiichi Sankyo : Speaker honoraria Alexion : Steering committee - National Coordinator - ANNEXa-i Bristol Myers Squibb : Steering Committee National Coordinator - AXIOMATIC</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bristol Myers Squibb : National Coordinator - Clinical trial</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology. Secretary General of the European Stroke Organisation</p>
	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Daiichi Sankyo : Stroke</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bristol Myers Squibb : Stroke Alexion : Stroke</p>
	<p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Daiichi Sankyo : Stroke</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Bristol Myers Squibb : Stroke Bayer AG : Stroke Astrazeneca : Stroke</p>

2024 ESC Guidelines for the management of elevated blood pressure and hypertension - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry	
Sandset Else Charlotte	2023	<p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Vice Editor of the European Stroke Journal Editorial Board of the journals Neurology (American Academy of Neurology) and Stroke (AHA/ASA) Editorial Consultant of the Lancet Neurology Chair of European Stroke Organisation Guideline Working Group for guidelines on Blood pressure management in acute ischaemic stroke and intracerebral haemorrhage. Member of the Guideline Working group of ESO Intracerebral Haemorrhage Guidelines. Secretary General of the European Stroke Organisation 2019-2023</p>
Scheenaerts Bart	2021	<p>Travel and meeting support from healthcare industry, independent of the above activities. Oxford University : Visual rehabilitation after stroke study, as participant in the study</p>
	2022	<p>Travel and meeting support from healthcare industry, independent of the above activities. University of Oxford : Stroke</p>
	2023	Nothing to be declared
Staessen Jan Albert	2021	<p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Alliance for the Promotion of Preventive Medicine (APPREMED) : Preventive Medicine</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology. Diabetes Liga, Gent, Belgium - regular membership - no fees</p>
	2022	Nothing to be declared
	2023	<p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Not-for-Profit Research Association Alliance for the Promotion of Preventive Medicine (URL: www.appremed.org)</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). OMRON supports the Alliance for the Promotion of Preventive Medicine by a non-binding grant. According to the by-laws of this VZW (Belgian registration number: 739849385), none of the proceeds of the association can be transferred to myself (Chair of the Board) or to any of the four Board Members. All proceeds should be re-invested in research or patient services. Details of the legal structure and balance sheets are available at the crossroads bank of Belgian enterprises (https://kbopub.economie.fgov.be/kbopub/zoeknummerform.html?nummer=739849385&actionLu=Zoek). The by-laws have been published in the Belgian National Gazette on 19 December 2019. The VZW is audited by Konsilanto (www.konsilanto.be). In short, support by OMRON is not a personal income.</p>
Touyz Rhian	2021	Nothing to be declared

2024 ESC Guidelines for the management of elevated blood pressure and hypertension - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry	
Touyz Rhian	2022	Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. Editor-in-Chief, Hypertension, American Heart Association Member of guideline committee on 'Aldosterone', Endocrine Society
	2023	Membership or affiliation in political or advocacy groups working in the field of cardiology. American Heart Association Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Editor-in-Chief, Hypertension, American Heart Association Guest editor, Canadian Journal of Cardiology Hyperaldosteronism guidelines, Endocrine Society, USA
Uchmanowicz Izabella	2021	Nothing to be declared
	2022	Nothing to be declared
	2023	Nothing to be declared
Volterrani Maurizio	2021	Nothing to be declared
	2022	Nothing to be declared
	2023	Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Editor in Chief of the Monaldi Archive for Chest Diseases

2024 ESC Guidelines for the management of elevated blood pressure and hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Abdessalem Salem	2022	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Menarini : Basic Science Alfa-Wassermann : Other Servier : Training and Education</p> <p>Direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease. Healthcare - Basic Science - PolyPath HealthTech Company: Device for microcirculation and endothelial dysfunction assessment</p>
	2023	<p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Boehringer-Ingelheim : Chronic Heart Failure, Training and Education</p> <p>Direct financial interest in healthcare, media, education companies, or in companies related to or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease. Healthcare - Basic Science - PolyPath HealthTech Company: Device for microcirculation and endothelial dysfunction assessment</p>
Abreu Ana	2022	Nothing to be declared
	2023	<p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Daiichi Sankyo : Risk Factors and Prevention, Pharmacology and Pharmacotherapy Ferrer Internacional : Risk Factors and Prevention, Pharmacology and Pharmacotherapy</p>
Agathangelou Petros	2022	Nothing to be declared
	2023	Nothing to be declared
Ambrosetti Marco	2022	Nothing to be declared
	2023	Nothing to be declared
Androulakis Emmanouil	2022	Nothing to be declared
	2023	Nothing to be declared

2024 ESC Guidelines for the management of elevated blood pressure and hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Badariene Jolita	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Berlin Menarini : Hypertension Amgen : Other Novartis : Risk Factors and Prevention Servier : Risk Factors and Prevention Krka Pharma : Risk Factors and Prevention</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. Novartis : Other Krka Pharma : Other</p>
	<p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Berlin Menarini : Hypertension Novartis : Risk Factors and Prevention Servier : Risk Factors and Prevention Krka Pharma : Risk Factors and Prevention Amgen : Risk Factors and Prevention, Other</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Novartis : Other Krka Pharma : Other</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Badila Elisabeta	2022	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bayer : Atrial Fibrillation (AF) Astra Zeneca : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Novartis : Chronic Heart Failure Servier : Hypertension Labormed : Hypertension Krka Pharma : Risk Factors and Prevention</p>
	2023	<p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Vifor Pharma Romania SRL : Chronic Heart Failure TERAPIA SA : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Servier : Hypertension Labormed : Hypertension Berlin Chemie A. Menarini SRL : Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure BGP Products : Risk Factors and Prevention</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Berlin Chemie AG : Chronic Heart Failure Servier : Other</p>
Bang Lia Evi	2022	Nothing to be declared
	2023	Nothing to be declared
Banu Cristiana	2022	Nothing to be declared
	2023	Nothing to be declared

2024 ESC Guidelines for the management of elevated blood pressure and hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Barakat Elias	2022	Nothing to be declared
	2023	Nothing to be declared
Bech Jesper	2022	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bayer AG : Hypertension, Pharmacology and Pharmacotherapy, Other Astra Zeneca : Other</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. Astra Zeneca : Other</p>
	2023	<p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Bayer AG : Hypertension, Pharmacology and Pharmacotherapy, Other Astra Zeneca : Other</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Astra Zeneca : Other</p>
Bilo Grzegorz	2022	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Daiichi Sankyo : Risk Factors and Prevention, Pharmacology and Pharmacotherapy</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). OMRON Healthcare : blood pressure monitoring (study of novel BP devices), investigator Menarini : hypertension and risk factors in peruvian highlanders and lowlanders (epidemiological study), investigator</p>
	2023	<p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Italian Ministry of Health</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Viatrix : Hypertension Servier : Hypertension, Risk Factors and Prevention AlfaSigma : Hypertension, Risk Factors and Prevention</p>

2024 ESC Guidelines for the management of elevated blood pressure and hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Bilo Grzegorz	2023	Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Associate Editor, "Blood Pressure Monitoring Journal"
Bini Roberto	2022	Nothing to be declared
	2023	Nothing to be declared
Borger Michael A	2022	Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Artivion (formerly CryoLife) : Diseases of the Aorta Abbott : Valvular Heart Disease Edwards Lifesciences : Valvular Heart Disease Medtronic : Valvular Heart Disease
	2023	Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Artivion (formerly CryoLife) : Diseases of the Aorta Abbott : Valvular Heart Disease Edwards Lifesciences : Valvular Heart Disease Medtronic : Valvular Heart Disease
Bosevski Marijan	2022	Nothing to be declared
	2023	Nothing to be declared
Boskovic Aneta	2022	Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Boehringer-Ingelheim : Atrial Fibrillation (AF) Bayer : Atrial Fibrillation (AF), Pharmacology and Pharmacotherapy Astra Zeneca : Chronic Heart Failure

2024 ESC Guidelines for the management of elevated blood pressure and hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Boskovic Aneta	2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Boehringer-Ingelheim : Atrial Fibrillation (AF) Bayer : Atrial Fibrillation (AF), Pharmacology and Pharmacotherapy Astra Zeneca : Chronic Heart Failure
Boulestreau Romain	2022 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bayer : Atrial Fibrillation (AF) Novartis : Chronic Heart Failure Astra Zeneca : Hypertension Medtronic : Hypertension Servier : Hypertension Recordati International : Hypertension Lilly : Risk Factors and Prevention <hr style="border-top: 1px dashed black;"/> 2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Novartis : Chronic Heart Failure Medtronic : Hypertension Servier : Hypertension Recordati International : Hypertension Lilly : Risk Factors and Prevention
Boutouyrie Pierre	2022 Nothing to be declared <hr style="border-top: 1px dashed black;"/> 2023 Nothing to be declared

2024 ESC Guidelines for the management of elevated blood pressure and hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Brady Adrian Jb	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Daiichi Sankyo : Atrial Fibrillation (AF) Sanofi Aventis : Atrial Fibrillation (AF) Novartis : Chronic Heart Failure Amgen : Pharmacology and Pharmacotherapy</p>
	<p>2023</p> <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one’s ability to join an ESC activity Scottish Heart and arterial Disease PRevention</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Daiichi Sankyo : Risk Factors and Prevention Novartis : Risk Factors and Prevention</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. President, Scottish Cardiac Society Council, British Cardiovascular Society</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Editorial board, Br J Cardiology</p>
Bronze Carvalho Luis	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Servier : Hypertension, Training and Education JaBA Recordati : Hypertension, Training and Education</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. Servier : Hypertension</p>

2024 ESC Guidelines for the management of elevated blood pressure and hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Bronze Carvalho Luis	<p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Merck Portugal : Hypertension Servier : Hypertension, Training and Education JaBA Recordati : Hypertension, Training and Education</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Servier : Hypertension</p>
Buccheri Sergio	<p>2022 Nothing to be declared</p> <hr style="border-top: 1px dashed black;"/> <p>2023 Nothing to be declared</p>
Burkard Thilo	<p>2022</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Medtronic : Hypertension Servier : Risk Factors and Prevention Sanofi Aventis : Risk Factors and Prevention</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Medtronic : Local principal investigator in the GSR define Registry for Renal Denervation, Local PI Roche Diagnostics : Research funding for biomarker analysis within an investigator initiated registry for women with postpartum hypertension, Sponsor of the trial Astra Zeneca : Sponsoring of the research funds of the Medical Outpatient Department, Committee research funds Medtronic : Sponsoring of the research funds of the Medical Outpatient Department, Committee research funds Collabree : Trial: A targeted behavioral economics-based intervention to improve medication adherence in patients with hypertension, Local Principal investigator</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. International Society of Hypertension Fellow Member European Society of Hypertension Member Swiss Society of Hypertension Member Swiss Society of Cardiology</p>

2024 ESC Guidelines for the management of elevated blood pressure and hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Burkard Thilo	<p>2023</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Daiichi Sankyo : Risk Factors and Prevention Servier : Risk Factors and Prevention Sanofi Aventis : Risk Factors and Prevention Novo-Nordisk : Risk Factors and Prevention</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Novartis : 2 Lipid lowering studies, Local PI Medtronic : Participation in the GSR Define Registry for renal deneravtion, Local PI Collabree : Trial: A targeted behavioral economics-based intervention to improve medication adherence in patients with hypertension, Local Principal investigator</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. International Society of Hypertension Fellow Member European Society of Hypertension Member Swiss Society of Hypertension Member Swiss Society of Cardiology Member European Atherosclerosis Society</p>
Carau Alexandru	<p>2022 Nothing to be declared</p> <hr style="border-top: 1px dashed black;"/> <p>2023 Nothing to be declared</p>
Dalmau Regina	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Amgen : Risk Factors and Prevention Novartis : Risk Factors and Prevention Sanofi Aventis : Risk Factors and Prevention Ferrer Internacional : Risk Factors and Prevention Novo-Nordisk : Risk Factors and Prevention</p>

2024 ESC Guidelines for the management of elevated blood pressure and hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Dalmau Regina	<p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Amgen : Risk Factors and Prevention Novartis : Risk Factors and Prevention Sanofi Aventis : Risk Factors and Prevention Ferrer Internacional : Risk Factors and Prevention Novo-Nordisk : Risk Factors and Prevention</p>
De Pablo Zarzosa Maria Carmen	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Ferrer Internacional : Rehabilitation and Sports Cardiology Amgen : Risk Factors and Prevention Daiichi Sankyo : Risk Factors and Prevention Servier : Risk Factors and Prevention, Rehabilitation and Sports Cardiology Spanish Society of Cardiology : Risk Factors and Prevention, Rehabilitation and Sports Cardiology</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. Novartis : Risk Factors and Prevention</p> <hr style="border-top: 1px dashed black;"/> <p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Amgen : Risk Factors and Prevention Novartis : Risk Factors and Prevention, Rehabilitation and Sports Cardiology Servier : Risk Factors and Prevention, Rehabilitation and Sports Cardiology Spanish Society of Cardiology : Risk Factors and Prevention, Rehabilitation and Sports Cardiology</p> <p>Receipt of royalties for intellectual property. Editorial PANAMERICANA : Risk Factors and Prevention, Rehabilitation and Sports Cardiology</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Editorial committee of: CARDIO CLINC (Spanish Journal of Cardiology)</p>
Delles Christian	<p>2022</p> <p>Nothing to be declared</p>

2024 ESC Guidelines for the management of elevated blood pressure and hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Delles Christian	2023 Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity British Heart Foundation European Commission Wellcome
Dolan Eamon	2022 Nothing to be declared <hr style="border-top: 1px dashed black;"/> 2023 Nothing to be declared
Dores Helder	2022 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Servier : Risk Factors and Prevention Menarini : Risk Factors and Prevention Bial Portela : Risk Factors and Prevention Medinfar : Risk Factors and Prevention <hr style="border-top: 1px dashed black;"/> 2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Daiichi Sankyo : Other Servier : Risk Factors and Prevention Menarini : Risk Factors and Prevention Bial Portela : Risk Factors and Prevention Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Medinfar : Other

2024 ESC Guidelines for the management of elevated blood pressure and hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Doroszko Adrian	2022	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Servier : Atrial Fibrillation (AF), Hypertension, Risk Factors and Prevention Bausch Health : Chronic Heart Failure, Pharmacology and Pharmacotherapy Bayer : Peripheral Vascular and Cerebrovascular Disease, Stroke, Risk Factors and Prevention, Pharmacology and Pharmacotherapy</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. Servier : Hypertension</p>
	2023	<p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Servier : Atrial Fibrillation (AF), Hypertension, Risk Factors and Prevention Bausch Health : Chronic Heart Failure, Pharmacology and Pharmacotherapy Polpharma : Other Novo-Nordisk : Other Bayer : Peripheral Vascular and Cerebrovascular Disease, Stroke, Risk Factors and Prevention, Pharmacology and Pharmacotherapy</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Servier : Hypertension</p>
El Kilany Wael Mahmoud	2022	Nothing to be declared
	2023	Nothing to be declared
Fiuza Maria Manuela	2022	Nothing to be declared
	2023	Nothing to be declared

2024 ESC Guidelines for the management of elevated blood pressure and hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Fras Zlatko	2022	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Amgen : Risk Factors and Prevention Boehringer-Ingelheim : Risk Factors and Prevention Novartis : Risk Factors and Prevention Novo-Nordisk : Risk Factors and Prevention Krka Pharma : Risk Factors and Prevention Sanofi Aventis : Risk Factors and Prevention, Rehabilitation and Sports Cardiology</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Novartis : HORIZON Trial; VICTORION-2P Trial, site PI; nat coord</p>
	2023	<p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Slovenian National Research Agency</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Swixx Biopharma : Cardiovascular Disease in Special Populations Amgen : Risk Factors and Prevention Novartis : Risk Factors and Prevention Novo Nordisk : Risk Factors and Prevention</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Novartis : Clinical Studies HORIZON and VICTORION-2-P, PI</p>
Gabulova Rahima	2022	Nothing to be declared
	2023	Nothing to be declared
Gunes Yilmaz	2022	Nothing to be declared
	2023	Nothing to be declared

2024 ESC Guidelines for the management of elevated blood pressure and hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Haugen Bjorn Olav	2022	Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bayer : Risk Factors and Prevention
	2023	Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca : Chronic Heart Failure Novartis : Risk Factors and Prevention Novo-Nordisk : Risk Factors and Prevention
Heiss Christian	2022	Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bayer Healthcare : Peripheral Vascular and Cerebrovascular Disease
	2023	Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity EPSRC Impact Acceleration Account EU Medical Research Council Membership or affiliation in political or advocacy groups working in the field of cardiology. European Society of Vascular Medicine, German Society of Vascular Medicine, British Cardiovascular Society, The Vascular Society for Great Britain and Ireland, German Society of Cardiology, Royal Society of Medicine, Royal College of Physicians, UEMS Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Associate Editor VASA
Hrafnkelsdottir Thordis	2022	Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Chronic Heart Failure Pfizer : Myocardial Disease Travel and meeting support from healthcare industry, independent of the above activities. Novo-Nordisk : Training and Education

2024 ESC Guidelines for the management of elevated blood pressure and hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Hrafnkelsdottir Thordis	<p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca : Chronic Heart Failure</p>
Ibanez Borja	<p>2022</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. My center (CNIC) is a public non-profit institution that receives Royalties for the sale of a polypill containing aspirin, ramipril and atorvastatin (trinomía, sincronium). I am not involved in the development I do NOT receive any personal benefit (neither direct nor indirect).</p>
	<p>2023</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). My center (CNIC) is a public non-profit institution that receives Royalties for the sale of a polypill containing aspirin, ramipril and atorvastatin (trinomía, sincronium). I am not involved in the development I do NOT receive any personal benefit (neither direct nor indirect).</p>
James Stefan	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Medtronic : Valvular Heart Disease</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Amgen : Executive committee member, Executive committee member Janssen-Cilag : Executive committee member, Executive committee member Astra Zeneca : Study PI , Prinicpal investigator</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. Swedish medical Association, Swedish cardiac society</p>

2024 ESC Guidelines for the management of elevated blood pressure and hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

James Stefan	<p>2023</p> <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Wallenberg foundation, Swedish heart and lung foundation</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Medtronic : Valvular Heart Disease</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Elixir : clinical trial, study chair MSD : Clinical trial, trial executive committee Amgen : Executive committee member, Executive committee member Janssen-Cilag : Executive committee member, Executive committee member Astra Zeneca : Study PI , Principal investigator</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. Swedish medical Association, Swedish cardiac society</p>
Kapil Vikas	<p>2022</p> <p>Nothing to be declared</p> <hr style="border-top: 1px dashed black;"/> <p>2023</p> <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Barts Charity NIHR</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Associate editor, Clinical Medicine, Royal College of Physicians London publications Consulting editor, British Journal of Pharamcology, British Pharmacological Society publications</p>
Kayikcioglu Meral	<p>2022</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Abbott : Hypertension, Risk Factors and Prevention Abdi Ibrahim : Hypertension, Risk Factors and Prevention LIB Therapeutics : Risk Factors and Prevention</p>

2024 ESC Guidelines for the management of elevated blood pressure and hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Kayikcioglu Meral	2022	<p>Membership or affiliation in political or advocacy groups working in the field of cardiology. Familial hypercholesterolemia Turkey (patient association)</p>
	2023	<p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Abbott : Hypertension, Risk Factors and Prevention Abdi Ibrahim : Hypertension, Risk Factors and Prevention Chiesi Pharma : Risk Factors and Prevention LIB Therapeutics : Risk Factors and Prevention</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. Familial hypercholesterolemia Turkey (patient association) FH Europe</p>
Khamidullaeva Gulnoz	2022	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Polpharma : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Abbott : Hypertension Servier : Hypertension Promed : Stroke, Hypertension</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. Servier : Hypertension Abbott : Risk Factors and Prevention</p>
	2023	<p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Abbott : Hypertension Polpharma : Hypertension</p>

2024 ESC Guidelines for the management of elevated blood pressure and hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Kintscher Ulrich	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Servier : Hypertension, Risk Factors and Prevention, Pharmacology and Pharmacotherapy Bayer Vital : Risk Factors and Prevention, Pharmacology and Pharmacotherapy Amarin : Risk Factors and Prevention, Pharmacology and Pharmacotherapy</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. Member of the German Hypertension Society Member of the European Society of Hypertension Fellow of the American Heart Association Member of the International Society of Heart Research</p>
	<p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Oviva : Hypertension Streamed Up : Hypertension Novartis : Pharmacology and Pharmacotherapy Sanofi Aventis : Risk Factors and Prevention</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Sanofi Aventis : Risk Factors and Prevention</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. Member of the German Hypertension Society Member of the European Society of Hypertension Fellow of the American Heart Association Member of the International Society of Heart Research</p>
Kiwan Ghassan S	<p>2022</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. Governor ACC Lebanese Chapter /</p>
	<p>2023</p> <p>Nothing to be declared</p>

2024 ESC Guidelines for the management of elevated blood pressure and hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Kober Lars	2022	Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Chronic Heart Failure Bayer : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Novartis : Chronic Heart Failure
	2023	Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Novartis : Chronic Heart Failure Novo-Nordisk : Chronic Heart Failure
Koskinas Konstantinos	2022	Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Amgen : Risk Factors and Prevention Daiichi Sankyo : Risk Factors and Prevention Sanofi Aventis : Risk Factors and Prevention Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Novartis : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)
	2023	Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Amgen : Risk Factors and Prevention Daiichi Sankyo : Risk Factors and Prevention Sanofi Aventis : Risk Factors and Prevention
Laredj Nadia	2022	Nothing to be declared
	2023	Nothing to be declared

2024 ESC Guidelines for the management of elevated blood pressure and hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Laukkanen Jari Antero	2022	Nothing to be declared
	2023	Nothing to be declared
Locati Emanuela Teresa	2022	Nothing to be declared
	2023	Nothing to be declared
Macdonald Sharon	2022	Nothing to be declared
	2023	Nothing to be declared
Marketou Maria	2022	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Boehringer-Ingelheim : Chronic Heart Failure Astra Zeneca : Risk Factors and Prevention Ferrer Internacional : Risk Factors and Prevention, Rehabilitation and Sports Cardiology</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Boehringer-Ingelheim : Chronic Heart Failure</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. Bayer : Cardiovascular Disease in Special Populations Novartis : Chronic Heart Failure</p>
	2023	<p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca : Chronic Heart Failure Ferrer Internacional : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Medtronic : Hypertension Servier : Hypertension</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Servier : Hypertension</p>

2024 ESC Guidelines for the management of elevated blood pressure and hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Mazon Ramos Pilar	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bayer : Atrial Fibrillation (AF) Daiichi Sankyo : Atrial Fibrillation (AF) Astra Zeneca : Chronic Heart Failure Servier : Hypertension Almirall Spain : Other Spanish Society of Cardiology : Risk Factors and Prevention Esteve : Risk Factors and Prevention Novo-Nordisk : Risk Factors and Prevention</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Novo-Nordisk : Clinical trial (SOUL), PI</p>
	<p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Bayer : Atrial Fibrillation (AF) Daiichi Sankyo : Atrial Fibrillation (AF) Astra Zeneca : Chronic Heart Failure Servier : Hypertension Almirall Spain : Other Spanish Society of Cardiology : Risk Factors and Prevention Esteve : Risk Factors and Prevention Novo-Nordisk : Risk Factors and Prevention</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Novo-Nordisk : Clinical trial (SOUL), PI</p>
Mercieca Balbi Matthew	<p>2022</p> <p>Nothing to be declared</p>
	<p>2023</p> <p>Nothing to be declared</p>

2024 ESC Guidelines for the management of elevated blood pressure and hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Midtboe Helga	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bayer : Other</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. Norwegian society of Hypertension, Norwegian society of cardiology</p>
	<p>2023</p> <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Hjertefondet and Meltzer fondation, University of Bergen</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Bayer : Cardiovascular Disease in Special Populations Pfizer : Cardiovascular Disease in Special Populations Boehringer Ingelheim : Cardiovascular Disease in Special Populations</p>
Mihailidou Anastasia S	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Medtronic : Hypertension</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. Medtronic : Hypertension</p>
	<p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Medtronic : Hypertension</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Medtronic : Hypertension</p>
Mihaylova Borislava	<p>2022</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Merck Sharp & Dohme : economic analyses alongside a clinical trial, senior health economist Barts Charity : Research project, principal investigator National Institute for Health Research (UK), Health Technology Assessment Programme : Research project, principal investigator Bowel Research UK : research project, principal investigator</p>

2024 ESC Guidelines for the management of elevated blood pressure and hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Mihaylova Borislava	<p>2023</p> <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity</p> <p>Barts Charity, UK Bowel Research UK Cancer Research UK National Institute for Health and Care Research, UK</p>
Mindham Richard	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. PASSpaces. http://passpaces.co.uk/. PASSpaces tutors young British doctors to help them pass their medical examinations. I "act" as a patient, permitting the trainee to take a patient history. : Training and Education</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. European Society of Cardiology. Payment of hotel, travel and meals to attend or speak at ESC conferences. : European Society of Cardiology</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. I support the British charity CardiomyopathyUK, https://www.cardiomyopathy.org.uk/. I make small financial contributions to support their activities. I support the British charity Pumping Marvellous, https://pumpingmarvellous.org/. I make no financial contributions to the charity's activities. I am a member of the Coalition for Reducing Bureaucracy in Clinical Trials, https://bureaucracyincts.eu/. The Coalition is a collection of researchers, clinicians and patients which advocates for the reduction of bureaucracy in clinical trials, chiefly in the EU. I have no financial interest in the Coalition.</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. I have savings and pensions held in shares. The shares are managed by a financial adviser; I do not not control the purchase & sale of shares and I do not know whether any shares are in medical companies.</p>

2024 ESC Guidelines for the management of elevated blood pressure and hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Mindham Richard	<p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. NiCE (National Institute for Health & Care Excellence) - UK Government body. Guideline development.. Commences January 2024. : Chronic Heart Failure</p> <p>PASSpaces. http://passpaces.co.uk/. PASSpaces tutors young British doctors to help them pass their medical examinations. I "act" as a patient, permitting the trainee to take a patient history. : Training and Education</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. European Society of Cardiology. Payment of hotel, travel and meals to attend or speak at ESC conferences. : European Society of Cardiology</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. I support the British charity CardiomyopathyUK, https://www.cardiomyopathy.org.uk/. I make small financial contributions to support their activities. I support the British charity Pumping Marvellous, https://pumpingmarvellous.org/. I make no financial contributions to the charity's activities. I am a member of the Coalition for Reducing Bureaucracy in Clinical Trials, https://bureaucracyincts.eu/. The Coalition is a collection of researchers, clinicians and patients which advocates for the reduction of bureaucracy in clinical trials, chiefly in the EU. I have no financial interest in the Coalition.</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). I have savings and pensions held in shares. The shares are managed by a financial adviser; I do not not control the purchase & sale of shares and I do not know whether any shares are in medical companies.</p>
Mirrakhimov Erkin	<p>2022 Nothing to be declared</p> <hr style="border-top: 1px dashed black;"/> <p>2023 Nothing to be declared</p>
Mirzoyev Ulvi	<p>2022 Nothing to be declared</p> <hr style="border-top: 1px dashed black;"/> <p>2023 Nothing to be declared</p>

2024 ESC Guidelines for the management of elevated blood pressure and hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Mortensen Martin Bodtker	2022	Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Amgen : Risk Factors and Prevention Astra Zeneca : Risk Factors and Prevention Novo-Nordisk : Risk Factors and Prevention Amarin : Risk Factors and Prevention
	2023	Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Novo-Nordisk : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS), Risk Factors and Prevention Amgen : Risk Factors and Prevention Astra Zeneca : Risk Factors and Prevention Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Novo-Nordisk : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)
Mouine Najat	2022	Nothing to be declared
	2023	Nothing to be declared
Msalam Omar	2022	Nothing to be declared
	2023	Nothing to be declared
Nardai Sandor	2022	Nothing to be declared
	2023	Nothing to be declared
Neubeck Lis	2022	Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Pfizer : Atrial Fibrillation (AF),

2024 ESC Guidelines for the management of elevated blood pressure and hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Neubeck Lis	<p>2023</p> <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Burdett Trust for Nursing Chief Scientists Office</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Sanofi Aventis : Risk Factors and Prevention</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Daiichi Sankyo : Atrial fibrillation screening, Principal Investigator</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Consultant Editor British Journal of Cardiac Nursing</p>
Nielsen Jens Cosedis	<p>2022</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. Have received research funding to my institution for independent research from the Danish Heart Foundation and the Novo Nordisk Foundation.</p> <hr style="border-top: 1px dashed black;"/> <p>2023</p> <p>Nothing to be declared</p>
Nilsson Peter M	<p>2022</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Novartis : Support for observational study of patients escaping CVD in spite of risk factor burden, Investigator</p> <hr style="border-top: 1px dashed black;"/> <p>2023</p> <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Research Council of Sweden</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Novartis : Support for observational study of patients escaping CVD in spite of risk factor burden, Co-Investigator</p>

2024 ESC Guidelines for the management of elevated blood pressure and hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Olsen Michael Hecht	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Hypertension Novo-Nordisk : Risk Factors and Prevention</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Boehringer-Ingelheim : Developmant of an app to support doctors and patients in reducing cardiovascular risk factors according to guidelines using lifestyle changes and pharmacological treatment, Leading the project</p>
	<p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca : Hypertension Teva Pharmaceutical Industries : Hypertension Novo-Nordisk : Risk Factors and Prevention</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Boehringer-Ingelheim : Developmant of an app to support doctors and patients in reducing cardiovascular risk factors according to guidelines using lifestyle changes and pharmacological treatment, Leading the project</p>
Pall Denes	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Egis Pharma : Hypertension Teva Pharmaceutical Industries : Pharmacology and Pharmacotherapy Novo-Nordisk : Pharmacology and Pharmacotherapy</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Pharmacology and Pharmacotherapy Boehringer-Ingelheim : Pharmacology and Pharmacotherapy Novartis : Pharmacology and Pharmacotherapy Pfizer : Pharmacology and Pharmacotherapy Lilly : Pharmacology and Pharmacotherapy Novo-Nordisk : Pharmacology and Pharmacotherapy</p>

2024 ESC Guidelines for the management of elevated blood pressure and hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Pall Denes	<p>2023</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</p> <p>Astra Zeneca : Pharmacology and Pharmacotherapy Boehringer-Ingelheim : Pharmacology and Pharmacotherapy Novartis : Pharmacology and Pharmacotherapy Pfizer : Pharmacology and Pharmacotherapy Lilly : Pharmacology and Pharmacotherapy Novo-Nordisk : Pharmacology and Pharmacotherapy</p>
Pasquet Agnes A	<p>2022</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <p>Philips : Echocardiography, Interventional Cardiology Daiichi Sankyo : Hypertension Servier : Other</p> <hr style="border-top: 1px dashed black;"/> <p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</p> <p>Servier : Hypertension</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</p> <p>Servier : Hypertension</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility.</p> <p>Philips : echography, contribution and support</p>

2024 ESC Guidelines for the management of elevated blood pressure and hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Pauklin Priit	2022 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bayer : Atrial Fibrillation (AF) Servier : Hypertension Berlin Chemie AG : Hypertension Travel and meeting support from healthcare industry, independent of the above activities. Abbott : Arrhythmias, General
	2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Bayer : Arrhythmias, General Servier : Arrhythmias, General Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Abbott : Arrhythmias, General Biosense Webster : Arrhythmias, General
Pavo Noemi	2022 Nothing to be declared
	2023 Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity OeNB (Österreichische Nationalbank), HFA of Austria Membership or affiliation in political or advocacy groups working in the field of cardiology. Board member of the HFA of Austria

2024 ESC Guidelines for the management of elevated blood pressure and hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

<p>Pedro Monica</p>	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Vifor International : Chronic Heart Failure</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Daiichi Sankyo : Cardiovascular Disease in Special Populations</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. Astra Zeneca : Chronic Heart Failure Vifor International : Chronic Heart Failure Pfizer : Other Servier : Training and Education</p> <hr style="border-top: 1px dashed black;"/> <p>2023</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Servier : 12 items checked Organon : 12 items checked Vifor International : Chronic Heart Failure, Acute Heart Failure Novartis : Risk Factors and Prevention, Other Servier : Training and Education</p>
<p>Postadzhiyan Arman</p>	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Chronic Heart Failure Servier : Hypertension Teva Pharmaceutical Industries : Hypertension Amgen : Risk Factors and Prevention Novartis : Risk Factors and Prevention Menarini : Risk Factors and Prevention</p>

2024 ESC Guidelines for the management of elevated blood pressure and hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Postadzhiyan Arman	<p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca : Chronic Heart Failure Servier : Hypertension Teva Pharmaceutical Industries : Hypertension Amgen : Risk Factors and Prevention Novartis : Risk Factors and Prevention Menarini : Risk Factors and Prevention</p>
Prescott Eva	<p>2022 Nothing to be declared</p> <hr style="border-top: 1px dashed black;"/> <p>2023 Nothing to be declared</p>
Rakischeva Amina	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Chronic Heart Failure Novartis : Chronic Heart Failure Roche Diagnostics : Chronic Heart Failure</p> <hr style="border-top: 1px dashed black;"/> <p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca : Chronic Heart Failure Novartis : Chronic Heart Failure Roche Diagnostics : Chronic Heart Failure</p>

2024 ESC Guidelines for the management of elevated blood pressure and hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Rietzschel Ernst	<p>2022</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Servier : Hypertension Galapagos : Other Daiichi Sankyo : Risk Factors and Prevention Novartis : Risk Factors and Prevention Amarin : Risk Factors and Prevention</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. Daiichi Sankyo : Risk Factors and Prevention</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Bristol Myers Squibb : Analyses for proteomics of diastolic heart failure, international consortium, Site investigator</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. President of the Belgian Lipid Club / Belgian Atherosclerosis Society (official Belgian representative EAS / IAS)</p>
------------------	---

2024 ESC Guidelines for the management of elevated blood pressure and hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Rietzschel Ernst	<p>2023</p> <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Ghent University Research fund</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Servier : Hypertension Galapagos : Other Daiichi Sankyo : Risk Factors and Prevention Novartis : Risk Factors and Prevention Amarin : Risk Factors and Prevention</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Daiichi Sankyo : Risk Factors and Prevention</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Bristol Myers Squibb : Analyses for proteomics of diastolic heart failure, international consortium, Site investigator</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. President of the Belgian Lipid Club / Belgian Atherosclerosis Society (official Belgian representative EAS / IAS)</p>
Rocca Bianca	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Aboca SRL : Other</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Bayer AG : study on low dose rivaroxaban, Chief investigator</p> <hr style="border-top: 1px dashed black;"/> <p>2023</p> <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Cancer UK</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Aboca, SRL : Other</p>

2024 ESC Guidelines for the management of elevated blood pressure and hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Rocca Bianca	2023	<p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations).</p> <p>Editorial Board of: Assistant Editor Diabetes and Vascular Disease Research Advisory Board: Pharmadvances. Associate Editor: Cardiovascular Drugs and Therapy, Clinical Pharmacology Editorial Board: Bleeding, Thrombosis, and Vascular Biology Associate Editor. Frontiers in Drug Safety and Regulation Section on Cardiovascular Drug Safety Associate Editor for European Cardiology Review Editorial Board European Journal of Preventive Cardiology Editorial Board Journal of Thrombosis and Thrombolysis Editorial Board International Journal of Cardiology</p>
Rossello Francisco Javier	2022	Nothing to be declared
	2023	Nothing to be declared
Samardzic Jure	2022	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <p>PLIVA : Acute Heart Failure Bayer : Atrial Fibrillation (AF) Astra Zeneca : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Servier : Hypertension</p>
	2023	<p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</p> <p>Bayer : Atrial Fibrillation (AF) Pfizer : Atrial Fibrillation (AF) Astra Zeneca : Chronic Heart Failure Viartis : Chronic Heart Failure</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</p> <p>PLIVA : Chronic Heart Failure</p>

2024 ESC Guidelines for the management of elevated blood pressure and hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Schmid Jean-Paul	2022	Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Daiichi Sankyo : Risk Factors and Prevention Sanofi Aventis : Risk Factors and Prevention Bayer AG : Risk Factors and Prevention Boehringer-Ingelheim : Risk Factors and Prevention, Rehabilitation and Sports Cardiology
	2023	Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Sanofi Aventis : Risk Factors and Prevention
Shantsila Eduard	2022	Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. MediWhale, South Korea/Singapore : Risk Factors and Prevention Research funding from healthcare industry under your direct/personal responsibility (to department or institution). MediWhale, South Korea/Singapore : Support of international PhD student (about 10K€/ year for 3 years). Most of the PhD costs are paid by the University of Liverpool and the student., Supervisor of the PhD
	2023	Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. MediWhale (South Korea) : Other
Shuka Naltin	2022	Nothing to be declared
	2023	Nothing to be declared
Simic Dragan	2022	Nothing to be declared
	2023	Nothing to be declared
Sirenko Yuriy	2022	Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Sandoz : Hypertension
	2023	Nothing to be declared
Sokolovic Sekib	2022	Nothing to be declared

2024 ESC Guidelines for the management of elevated blood pressure and hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Sokolovic Sekib	2023 Nothing to be declared
Spaak Jonas	2022 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Cardiovascular Disease in Special Populations Bayer : Cardiovascular Disease in Special Populations Sanofi Aventis : Cardiovascular Disease in Special Populations Medtronic : Hypertension Neko Health : Risk Factors and Prevention Research funding from healthcare industry under your direct/personal responsibility (to department or institution). HJN Sverige : Funding to evaluate a novel device to measure arterial stiffness in a small group of volunteers (n=31), PI Direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease. Healthcare - Cross-Modality and Multi-Modality Imaging Topics - Small shareholder (value <10K Euro) in Beat Vascular Healt Inc, a startup medtech company developing software to model the arterial system including stenoses and arterial stiffness.

2024 ESC Guidelines for the management of elevated blood pressure and hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Spaak Jonas	<p>2023</p> <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Karolinska Institutet Region Stockholm Research Grant Swedish Heart-Lung Foundation</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca : Cardiovascular Disease in Special Populations Bayer : Cardiovascular Disease in Special Populations Boehringer-Ingelheim : Cardiovascular Disease in Special Populations Sanofi Aventis : Cardiovascular Disease in Special Populations</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Neko Health : Funding to evaluate a novel device to measure arterial stiffness. Neko Health is sponsor, and J Spaak is clinical PI. The funding is received by Hospital and Karolinska Institutet., PI</p> <p>Direct financial interest in healthcare, media, education companies, or in companies related to or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease. Healthcare - Cross-Modality and Multi-Modality Imaging Topics - Small shareholder (value <5K Euro) in Beat Vascular Health Inc, a startup medtech company developing software to model the arterial system including stenoses and arterial stiffness.</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. -President Swedish society for hypertension, stroke and vascular medicine (SVM) -Board member Swedish Heart Association (Svenska Hjärtförbundet) -Advisory board VAS - European Independent Foundation in Angiology/Vascular Medicine -National representative on the European Union of Medical Specialists (UEMS) Division of Angiology</p>
Sudano Isabella	<p>2022</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. Amgen Inc : Risk Factors and Prevention</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. Swiss Society of hypertension, Swiss heart Foundation, Swiss Atherosclerosis society, Forum for Tobacco prevention in hospital setting Board Member, all voluntary participation</p>

2024 ESC Guidelines for the management of elevated blood pressure and hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Sudano Isabella	<p>2023</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Amgen : Risk Factors and Prevention Daiichi Sankyo : Risk Factors and Prevention Novartis : Risk Factors and Prevention Sanofi Aventis : Risk Factors and Prevention Recor Medical : Risk Factors and Prevention</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. Swiss Society of hypertension, Swiss heart Foundation, Swiss Atherosclerosis society, Forum for Tobacco prevention in hospital setting Board Member, all voluntary participation</p>
Timoteo Ana Teresa	<p>2022</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. Astra Zeneca : Chronic Heart Failure Servier : Chronic Heart Failure</p> <hr style="border-top: 1px dashed black;"/> <p>2023</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Associated Editor in Frontiers in Cardiovascular Imaging.</p>
Trusinskis Karlis	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Biotronik : Arrhythmias, General Bayer : Atrial Fibrillation (AF) Astra Zeneca : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Servier : Hypertension Berlin Menarini : Hypertension Novo-Nordisk : Risk Factors and Prevention</p>

2024 ESC Guidelines for the management of elevated blood pressure and hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Trusinskis Karlis	<p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</p> <p>Biotronik : Arrhythmias, General</p> <p>Bayer : Atrial Fibrillation (AF)</p> <p>Astra Zeneca : Chronic Heart Failure</p> <p>Boehringer-Ingelheim : Chronic Heart Failure</p> <p>Servier : Hypertension</p> <p>Berlin Menarini : Hypertension</p> <p>Novo-Nordisk : Risk Factors and Prevention</p>
Tsinamdzgvishvili Bezhan	<p>2022 Nothing to be declared</p> <hr style="border-top: 1px dashed black;"/> <p>2023 Nothing to be declared</p>
Tsvigoulis Georgios K	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <p>Novartis : Other</p> <p>Sanofi Aventis : Other</p> <p>Shire HGT : Other</p> <p>Biogen : Other</p> <p>Genesis Pharma : Other</p> <p>Bayer : Stroke</p> <p>Boehringer-Ingelheim : Stroke</p> <p>Medtronic : Stroke</p> <p>Bristol Myers Squibb : Stroke</p> <p>CSL Behring : Stroke</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <p>Amicus Therapeutics : Fabry disease, principal investigator</p>

2024 ESC Guidelines for the management of elevated blood pressure and hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Tsvigoulis Georgios K	<p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</p> <p>Novartis : Other Sanofi Aventis : Other Shire HGT : Other Biogen : Other Genesis Pharma : Other Bayer : Stroke Boehringer-Ingelheim : Stroke Medtronic : Stroke Bristol Myers Squibb : Stroke CSL Behring : Stroke</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility.</p> <p>Amicus Therapeutics : Fabry disease, principal investigator</p>
Tundybayeva Meiramgul	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <p>Roche Diagnostics : Chronic Heart Failure, Acute Coronary Syndromes, Hypertension Novartis : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Abbott : Hypertension Servier : Hypertension, Risk Factors and Prevention</p> <hr style="border-top: 1px dashed black;"/> <p>2023</p> <p>Nothing to be declared</p>
Ungar Andrea	<p>2022</p> <p>Nothing to be declared</p> <hr style="border-top: 1px dashed black;"/> <p>2023</p> <p>Nothing to be declared</p>
Vaartjes Ilonca	<p>2022</p> <p>Nothing to be declared</p> <hr style="border-top: 1px dashed black;"/> <p>2023</p> <p>Nothing to be declared</p>

2024 ESC Guidelines for the management of elevated blood pressure and hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

van de Borne Philippe	2022	Nothing to be declared
	2023	Nothing to be declared
Visseren Frank Lj	2022	Nothing to be declared
	2023	Nothing to be declared
Voller Heinz	2022	Nothing to be declared
	2023	Nothing to be declared
Vrints Christiaan J M	2022	Nothing to be declared
	2023	Nothing to be declared
Vromen Tom	2022	Nothing to be declared
	2023	Nothing to be declared
Widimsky Jiri	2022	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Servier, Zentiva, Recordati, Boehringer Ingelheim : Hypertension</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. Servier, Zentiva : Hypertension</p>
	2023	<p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Servier : Hypertension</p>
Witkowski Adam	2022	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Boston Scientific : Device Therapy Edwards Lifesciences : Device Therapy Medtronic : Device Therapy</p>

2024 ESC Guidelines for the management of elevated blood pressure and hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Witkowski Adam	<p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Boston Scientific : Device Therapy Edwards Lifesciences : Device Therapy Medtronic : Device Therapy</p>
Wolak Talya	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Boehringer-Ingelheim : Chronic Heart Failure</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. beyon air : Other</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Beyond Air : No treatment for viral pneumonia covid-19, principle investigator curespect : shock wave for treatment chronic renal failure and hypertension, principle investigator</p> <hr/> <p>2023</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Astrazeneca : microalbuminuria sign for unrecognized CKD, chief investigator</p>
Zennaro Maria-Christina	<p>2022</p> <p>Nothing to be declared</p> <hr/> <p>2023</p> <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity ANR French national research agency European Commission Horizon Europe Fondation pour la recherche médicale FRM H2020-MSCA-ITN-2020</p>
Zeppenfeld Katja	<p>2022</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Biosense Webster : Ventricular Arrhythmias and Sudden Cardiac Death (SCD)</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Biosense Webster : investigator initiated research, PI</p>

2024 ESC Guidelines for the management of elevated blood pressure and hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Zeppenfeld Katja	2023	<p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Biosense Webster : Ventricular Arrhythmias and Sudden Cardiac Death (SCD)</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Biosense Webster : Investigator initiated research, ventricular arrhythmias, PI</p>
------------------	-------------	---

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Arbelo Elena	2021 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Biosense Webster : Atrial fibrillation
	2022 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Biosense Webster : Atrial Fibrillation (AF)
	2023 Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Marató TV3 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Bayer : Atrial Fibrillation (AF) Biosense Webster : Atrial Fibrillation (AF)
Baigent Colin	2021 Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Boehringer-Ingelheim : Renal disease
	2022 Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Boehringer Ingelheim : Grant to the University of Oxford for the EMPA-KIDNEY trial, Co-PI
	2023 Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity UK Medical Research Council Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Boehringer-Ingelheim : Funding provided for the coordination of the EMPA-KIDNEY trial, Chair of Steering Committee
Borger Michael A	2021 Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Cryolife : aortic surgery Abbott : heart valve therapy Edwards Lifesciences : heart valve therapy Medtronic : heart valve therapy

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Borger Michael A	<p>2022 Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Artivion (formerly CryoLife) : Diseases of the Aorta Abbott : Valvular Heart Disease Edwards Lifesciences : Valvular Heart Disease Medtronic : Valvular Heart Disease</p>
	<p>2023 Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Artivion (formerly CryoLife) : Diseases of the Aorta Abbott : Valvular Heart Disease Edwards Lifesciences : Valvular Heart Disease Medtronic : Valvular Heart Disease</p>
Buccheri Sergio	<p>2021 Nothing to be declared</p>
	<p>2022 Nothing to be declared</p>
	<p>2023 Nothing to be declared</p>
Ibanez Borja	<p>2021 Nothing to be declared</p>
	<p>2022 Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. My center (CNIC) is a public non-profit institution that receives Royalties for the sale of a polypill containing aspirin, ramipril and atorvastatin (trinomía, sincronium). I am not involved in the development I do NOT receive any personal benefit (neither direct nor indirect).</p>
	<p>2023 Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). My center (CNIC) is a public non-profit institution that receives Royalties for the sale of a polypill containing aspirin, ramipril and atorvastatin (trinomía, sincronium). I am not involved in the development I do NOT receive any personal benefit (neither direct nor indirect).</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
James Stefan	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Medtronic : Proctorship</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Clinical trial executive committee Bayer : Clinical trial executive committee Elixir : Clinical trial executive committee jansen : Clinical trial executive committee Amgen : Clinical trial steering committee Novo-Nordisk : Clinical trial steering committee</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Astra Zeneca : Clinical trial Amgen : Clinical trial leadership Elixir : Clinical trial leadership</p> <hr style="border-top: 1px dashed black;"/> <p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Medtronic : Valvular Heart Disease</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Amgen : Executive committee member, Executive committee member Janssen-Cilag : Executive committee member, Executive committee member Astra Zeneca : Study PI , Principal investigator</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. Swedish medical Association, Swedish cardiac society</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
James Stefan	<p>2023</p> <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Wallenberg foundation, Swedish heart and lung foundation</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Medtronic : Valvular Heart Disease</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Elixir : clinical trial, study chair MSD : Clinical trial, trial executive committee Amgen : Executive committee member, Executive committee member Janssen-Cilag : Executive committee member, Executive committee member Astra Zeneca : Study PI , Principal investigator</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. Swedish medical Association, Swedish cardiac society</p>
Kober Lars	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Heart Failure Bayer : Heart Failure Boehringer-Ingelheim : Heart Failure Novartis : Heart Failure Novo-Nordisk : Heart Failure</p> <hr/> <p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Chronic Heart Failure Bayer : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Novartis : Chronic Heart Failure</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Kober Lars	<p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Novartis : Chronic Heart Failure Novo-Nordisk : Chronic Heart Failure</p>
Koskinas Konstantinos	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Amgen : Cardiology Daiichi Sankyo : Cardiology</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Novartis : Cardiology</p>
	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Amgen : Risk Factors and Prevention Daiichi Sankyo : Risk Factors and Prevention Sanofi Aventis : Risk Factors and Prevention</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Novartis : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)</p>
	<p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Amgen : Risk Factors and Prevention Daiichi Sankyo : Risk Factors and Prevention Sanofi Aventis : Risk Factors and Prevention</p>
Mcevoy John William	<p>2021</p> <p>Nothing to be declared</p>
	<p>2022</p> <p>Nothing to be declared</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry	
Mcevoy John William	2023	Nothing to be declared
Mihaylova Borislava	2021	<p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Merck Sharp & Dohme : Anacetrapib National Institute for Health Research (UK), Health Technology Assessment Programme : Cost-effectiveness of statin therapy Barts Charity : Digital pathology National Institute for Health Research : Various clinical studies including economic evaluations</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. I am a member of the Editorial Advisory Board of Value in Health (journal). I do not consider this to present any Col.</p>
	2022	<p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Merck Sharp & Dohme : economic analyses alongside a clinical trial, senior health economist Barts Charity : Research project, principal investigator National Institute for Health Research (UK), Health Technology Assessment Programme : Research project, principal investigator Bowel Research UK : research project, principal investigator</p>
	2023	<p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Barts Charity, UK Bowel Research UK Cancer Research UK National Institute for Health and Care Research, UK</p>
Mindham Richard	2021	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Imperial College, London : ONCE-OFF Honorarium, 2019, non-recurring, less than GB£900/€1000, passed in full to UK charity, CardiomyopathyUK</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. I have a pension and savings held in shares and funds. I do not control which shares are bought and I do not know whether any of them are invested in healthcare organisations as the shares are managed by a fund manager.</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Mindham Richard	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. PASSpaces. http://passpaces.co.uk/. PASSpaces tutors young British doctors to help them pass their medical examinations. I "act" as a patient, permitting the trainee to take a patient history. : Training and Education</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. European Society of Cardiology. Payment of hotel, travel and meals to attend or speak at ESC conferences. : European Society of Cardiology</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. I support the British charity CardiomyopathyUK, https://www.cardiomyopathy.org.uk/. I make small financial contributions to support their activities. I support the British charity Pumping Marvellous, https://pumpingmarvellous.org/. I make no financial contributions to the charity's activities. I am a member of the Coalition for Reducing Bureaucracy in Clinical Trials, https://bureaucracyincls.eu/. The Coalition is a collection of researchers, clinicians and patients which advocates for the reduction of bureaucracy in clinical trials, chiefly in the EU. I have no financial interest in the Coalition.</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. I have savings and pensions held in shares. The shares are managed by a financial adviser; I do not control the purchase & sale of shares and I do not know whether any shares are in medical companies.</p>
	<p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. NiCE (National Institute for Health & Care Excellence) - UK Government body. Guideline development.. Commences January 2024. : Chronic Heart Failure</p> <p>PASSpaces. http://passpaces.co.uk/. PASSpaces tutors young British doctors to help them pass their medical examinations. I "act" as a patient, permitting the trainee to take a patient history. : Training and Education</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. European Society of Cardiology. Payment of hotel, travel and meals to attend or speak at ESC conferences. : European Society of Cardiology</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Mindham Richard	<p>2023</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. I support the British charity CardiomyopathyUK, https://www.cardiomyopathy.org.uk/. I make small financial contributions to support their activities. I support the British charity Pumping Marvellous, https://pumpingmarvellous.org/. I make no financial contributions to the charity's activities. I am a member of the Coalition for Reducing Bureaucracy in Clinical Trials, https://bureaucracyincts.eu/. The Coalition is a collection of researchers, clinicians and patients which advocates for the reduction of bureaucracy in clinical trials, chiefly in the EU. I have no financial interest in the Coalition.</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). I have savings and pensions held in shares. The shares are managed by a financial adviser; I do not control the purchase & sale of shares and I do not know whether any shares are in medical companies.</p>
Neubeck Lis	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Pfizer : Atrial fibrillation</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology. Medical advisor to the Atrial Fibrillation Alliance</p> <hr/> <p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Pfizer : Atrial Fibrillation (AF),</p> <hr/> <p>2023</p> <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Burdett Trust for Nursing Chief Scientists Office</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Sanofi Aventis : Risk Factors and Prevention</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Daiichi Sankyo : Atrial fibrillation screening, Principal Investigator</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Consultant Editor British Journal of Cardiac Nursing</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry	
Nielsen Jens Cosedis	2021	Nothing to be declared
	2022	<p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. Have received research funding to my institution for independent research from the Danish Heart Foundation and the Novo Nordisk Foundation.</p>
	2023	Nothing to be declared
Pasquet Agnes A	2021	<p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Daiichi Sankyo : general cardiology Servier : general cardiology Philips : imaging</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology. member of the Belgian Society of Cardiology</p>
	2022	<p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Philips : Echocardiography, Interventional Cardiology Daiichi Sankyo : Hypertension Servier : Other</p>
	2023	<p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Servier : Hypertension</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Servier : Hypertension</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Philips : echography, contribution and support</p>
Prescott Eva	2021	Nothing to be declared

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry	
Prescott Eva	2022	Nothing to be declared
	2023	Nothing to be declared
Rakisheva Amina	2021	Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bayer : Atrial Fibrillatuion Novartis : Heart Failure
	2022	Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Chronic Heart Failure Novartis : Chronic Heart Failure Roche Diagnostics : Chronic Heart Failure
	2023	Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca : Chronic Heart Failure Novartis : Chronic Heart Failure Roche Diagnostics : Chronic Heart Failure
Rocca Bianca	2021	Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bayer AG : CV prevention in COVID pandemics SOBI : platelet growth factor Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Bayer AG : anticoagulant (rivaroxaban)
	2022	Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Aboca SRL : Other Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Bayer AG : study on low dose rivaroxaban, Chief investigator

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Rocca Bianca	<p>2023 Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Cancer UK</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Aboca, SRL : Other</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Editorial Board of: Assistant Editor Diabetes and Vascular Disease Research Advisory Board: Pharmadvances. Associate Editor: Cardiovascular Drugs and Therapy, Clinical Pharmacology Editorial Board: Bleeding, Thrombosis, and Vascular Biology Associate Editor. Frontiers in Drug Safety and Regulation Section on Cardiovascular Drug Safety Associate Editor for European Cardiology Review Editorial Board European Journal of Preventive Cardiology Editorial Board Journal of Thrombosis and Thrombolysis Editorial Board International Journal of Cardiology</p>
Rossello Francisco Javier	<p>2021 Nothing to be declared</p> <p>2022 Nothing to be declared</p> <p>2023 Nothing to be declared</p>
Vaartjes Ilonca	<p>2021 Nothing to be declared</p> <p>2022 Nothing to be declared</p> <p>2023 Nothing to be declared</p>
Vrints Christiaan Jm	<p>2021 Nothing to be declared</p> <p>2022 Nothing to be declared</p> <p>2023 Nothing to be declared</p>
Witkowski Adam	<p>2021 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Boston Scientific : coronary stents, IVUS, Accurate aortic valves (TAVI), Watchman (LAO) Medtronic : Evolute aortic valves (TAVI) Edwards Lifesciences : Sapien aortic valves (TAVI)</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Witkowski Adam	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Boston Scientific : Device Therapy Edwards Lifesciences : Device Therapy Medtronic : Device Therapy</p>
	<p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Boston Scientific : Device Therapy Edwards Lifesciences : Device Therapy Medtronic : Device Therapy</p>
Zeppenfeld Katja	<p>2021</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Biosense Webster : Research electrophysiology</p>
	<p>2022</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Biosense Webster : Ventricular Arrhythmias and Sudden Cardiac Death (SCD)</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Biosense Webster : investigator initiated research, PI</p>
	<p>2023</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Biosense Webster : Ventricular Arrhythmias and Sudden Cardiac Death (SCD)</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Biosense Webster : Investigator initiated research, ventricular arrhythmias, PI</p>